samedan logo
 
 
spacer
home > pmps > winter 2017 > whats the outcome
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Whats the Outcome

The global delivery of healthcare has become more focused on medical outcomes, achieving results for patients and tying industry incentives to those results. As with any fundamental change in business structure, this is happening slowly and at different rates around the world. The case for change, however, is strong and compelling.

Population growth and rising incomes create further demand for access to healthcare; incidences of lifestyle-related health conditions like diabetes occur more frequently; and technological innovation continues to support increasing targeted disease and associated therapy identification, whether through genetic analysis or the discovery and commercialisation of large molecule therapies like biologics. The value of the ensuing biologics market is forecast to grow by 60%, rising to a value of $291 billion annually between 2014 and 2020.

With a stronger focus on outcomes, it will not be sufficient for biopharmaceutical innovators to only think about the elements of the solution – like devices and connected services, for example – shortly before market launch. A more rounded approach to creating value in healthcare delivery is needed. Tactically, this requires evaluating the system holistically (what results will we deliver, and why?) as well as each strategic element (how will the conclusion be achieved?) at least three years prior to the treatment being made available (before Phase 3). In doing so, outcome delivery and improvements become integrated parts of the answer. It is all part of providing end-to-end solutions that are focused on results, as delivering these will equal income in the future for the industry.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bill Welch has over 25 years of contract design, development and manufacturing experience, primarily serving customers in the drug delivery, health technology and diagnostics markets. In his current capacity as Chief Technical Officer at Phillips-Medisize, he leads a global, over-500 person development, engineering, tooling, programme management and validation organisation with more than 75 concurrent schemes. Bill has been with Phillips-Medisize since 2002.
spacer
Bill Welch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Paradigm Clinical Research Names Industry Veteran Kurt Mussina as CEO as Expansion Plans Are Set in Motion


More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement